Follow the 参天製薬株式会社 stock price and the full directors' dealings record of the company, a publicly traded company based in Japan. Shares are quoted on the JP market, under the oversight of EDINET (Japan FSA). Operating in the Banks sector, 参天製薬株式会社 has recorded 25 reports. Market capitalisation: €40,269.7bn. The latest transaction was reported on 8 October 2025 (Holding update). Among the most active insiders: Silchester International Investors LLP. Every trade is openly available.
25
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate 参天製薬株式会社 Buy (bullish), based on 11 analysts. Average price target: JP¥3,596.
19Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 11,248 of 28,551 companies
56.9
score / 100
Value
37
Quality
77
FCF yld-59%
Earn yld6.0%
EV/EBITDA·
ROE9.4%
Gross mgn·
Net mgn32%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Santen Pharmaceutical Co., Ltd. es una empresa japonesa especializada en el sector farmacéutico, que ofrece productos para el cuidado de la salud y los ojos. Cotiza en la Bolsa de Tokio bajo el símbolo XTKS.